West Pharmaceutical (NYSE: WST) director granted 791 restricted stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Lockhart Stephen H reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services director Stephen H. Lockhart received an equity award of 791 shares of common stock. The award is structured as restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, he holds a total of 3,523.2615 shares directly. This is a compensation-related grant, not an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lockhart Stephen H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	791	$0.00	--

Holdings After Transaction: Common Stock — 3,523.262 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 791 shares Grant price: $0.0000 per share Post-transaction holdings: 3,523.2615 shares

3 metrics

RSU grant size 791 shares Restricted stock units granted to director on 2026-05-04

Grant price $0.0000 per share Reported transaction price for RSU grant

Post-transaction holdings 3,523.2615 shares Total common stock held directly after grant

Key Terms

restricted stock units, annual shareholder meeting, grant, award, or other acquisition, Form 4

4 terms

restricted stock units financial

"These shares of restricted stock units will vest in full on the date"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual shareholder meeting financial

"will vest in full on the date of the next annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/06/2026 - 05:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lockhart Stephen H

(Last)

(First)

(Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON

PENNSYLVANIA

19341

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/04/2026		A		791⁽¹⁾	A	$0	3,523.2615	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

	/s/ Louis Lalli, as an agent for Stephen H. Lockhart	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did WST director Stephen H. Lockhart report?

Stephen H. Lockhart reported receiving an equity award of 791 shares of West Pharmaceutical Services common stock. These shares are in the form of restricted stock units granted as compensation, rather than bought in the open market, and increase his direct holdings.

How many WST shares does Stephen H. Lockhart hold after this grant?

After the grant, Stephen H. Lockhart holds 3,523.2615 shares of West Pharmaceutical Services common stock directly. This total includes the 791-share restricted stock unit award reported in the filing, reflecting his updated ownership position following the compensation-related transaction.

What type of shares were granted to the WST director in this Form 4?

The director received 791 restricted stock units tied to West Pharmaceutical Services common stock. These units represent a right to receive shares in the future, rather than immediate freely tradable stock, and are typically subject to vesting conditions described in the filing footnote.

When will Stephen H. Lockhart’s WST restricted stock units vest?

The 791 restricted stock units granted to Stephen H. Lockhart will vest in full on the date of the next annual shareholder meeting. Vesting means the units convert into actual shares he owns outright, subject to the company’s normal equity plan terms.

Was Stephen H. Lockhart’s WST transaction a market purchase or sale?

No, the transaction was not a market purchase or sale. It is coded as a grant or award acquisition, meaning the 791 shares were granted as compensation, with a reported price per share of zero, rather than being bought or sold on the open market.

Does this WST Form 4 show any derivative securities for the director?

The filing’s derivative section is empty, indicating no derivative securities transactions were reported for Stephen H. Lockhart. The only reported activity is the non-derivative grant of 791 restricted stock units tied to West Pharmaceutical Services common stock.